alpha-1 liver disease - Business-News-Today.com

Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More

Business-News-Today.com

Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease

Aurobindo Pharma USA announces strategic partnership for respiratory drugs

Citi boosts Reliance Industries to ‘buy’ on improved market outlook

Northern California battered by deadly floods as atmospheric river unleashes record rainfall

Shocking mix-up in tortilla strips puts millions with wheat allergies at risk

Gulfstream Aerospace awarded $991m military logistics contract by U.S. Air Force

Bangladesh embraces innovation as AIMA electric motorbike debuts

Afcons Infrastructure sets new record with Rs 34,152cr order book and strong H1 FY25 performance

Sterlite Technologies appoints Rahul Puri as CEO to spearhead optical networking business growth

ONEOK to expand energy dominance with $4.3bn acquisition of EnLink Midstream units

Hanmi Pharmaceutical, Beijing Hanmi progress cancer therapy BH3120 with promising trial results

UAE arrests suspects in high-profile case involving Israeli rabbi’s murder

Massive Hezbollah rocket barrage shakes Tel Aviv as Israeli airstrike devastates Beirut

Cision partners with Google Cloud to transform AI-driven communication

KPMG and Google Cloud deepen alliance to drive generative AI and data analytics innovation

Ceasefire halts deadly Pakistan sectarian violence – is peace within reach?

Gautam Adani faces U.S. summons over multimillion-dollar bribery scheme

Tata Motors introduces first automated manual transmission truck in Saudi Arabia

U.S. Department of Energy launches $50m sodium-ion battery initiative

Mosque survey chaos: Three dead as mob-police clash intensifies in Uttar Pradesh

Horizon Petroleum secures key Polish concessions, advancing Lachowice gas project